The content of this presentation is provided to an audience of international healthcare professionals for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.
The European Society of Cardiology
Annual Congress 25-28 August 2023
Scientific publications at ESC Annual Congress 2023.
Thank you for your interest! Please see below to download the posters/presentations at ESC 2023. Presentations, Videos and Posters will be available following the presentation at the congress.
Some of the links to view the Presentations or Posters will link to the official ESC 2023 web page. You may need to be a registered delegate and logged in the respective platform to view the content.
Finerenone
August 28, 8.30-10.00 (9.06); Room Riga
Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: A FIDELITY analysis
Session: Advances in Science Presentation, Novel targets and treatments for heart diseases and diabetes Lead author: Ajay Singh
August 28, 8.30-10.00 (9.42); Room Riga
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis
Session: Advances in Science Presentation, Novel targets and treatments for heart diseases and diabetes Lead author: Robert Mentz
August 25, 15.15-16.00, Station 9
Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?
Session: Improving outcomes in heart failure: bench to bedside Lead author: Peter Kolkhof
